Hypertrophic cardiomyopathy
MONDO:0005045A condition in which the myocardium is hypertrophied without an obvious cause. The hypertrophy is generally asymmetric and may be associated with obstruction of the ventricular outflow tract.
Also known as: hypertrophic cardiomyopathy, hypertrophic subaortic stenosis, obstructive hypertrophic cardiomyopathy, familial hypertrophic cardiomyopathy, HCM - hypertrophic cardiomyopathy
314 clinical trials for this condition and its sub-types, 123 tagged with Hypertrophic cardiomyopathy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Hypertrophic cardiomyopathy
-
Non-familial hypertrophic cardiomyopathy 0 trials · 104 incl. sub-types
3 sub-types
- AL amyloidosis 93 trials · 99 incl. sub-types Sub-types →
- Cirrhotic cardiomyopathy 4 trials
- Hypertrophic cardiomyopathy due to intensive athletic training 1 trial
-
Familial hypertrophic cardiomyopathy 2 trials · 86 incl. sub-types
40 sub-types
- Myotonic dystrophy type 1 45 trials Sub-types →
- Noonan syndrome and Noonan-related syndrome 1 trial · 29 incl. sub-types Sub-types →
- Beckwith-Wiedemann syndrome 6 trials Sub-types →
- 46,XY complete gonadal dysgenesis 0 trials · 1 incl. sub-types Sub-types →
- Dilated cardiomyopathy 1C 1 trial
- Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency 1 trial
- Multiple acyl-CoA dehydrogenase deficiency 1 trial Sub-types →
- Very long chain acyl-CoA dehydrogenase deficiency 1 trial
- Cardiomyopathy, familial hypertrophic 27 0 trials
- Cardiomyopathy, familial hypertrophic, 23, with or without ventricular noncompaction 0 trials
- Cardiomyopathy, familial hypertrophic, 28 0 trials
- Cardiomyopathy, familial hypertrophic, 29, with polyglucosan bodies 0 trials
- Cardiomyopathy, familial hypertrophic, 30, atrial 0 trials
- Cardiomyopathy, familial hypertrophic, 31 0 trials
- Cardiomyopathy, familial restrictive, 5 0 trials
- Cardiomyopathy-hypotonia-lactic acidosis syndrome 0 trials
- Dilated cardiomyopathy 1KK 0 trials
- Hypertrophic cardiomyopathy 1 0 trials
- Hypertrophic cardiomyopathy 10 0 trials
- Hypertrophic cardiomyopathy 11 0 trials
- Hypertrophic cardiomyopathy 12 0 trials
- Hypertrophic cardiomyopathy 13 0 trials
- Hypertrophic cardiomyopathy 14 0 trials
- Hypertrophic cardiomyopathy 15 0 trials
- Hypertrophic cardiomyopathy 16 0 trials
- Hypertrophic cardiomyopathy 17 0 trials
- Hypertrophic cardiomyopathy 18 0 trials
- Hypertrophic cardiomyopathy 19 0 trials
- Hypertrophic cardiomyopathy 2 0 trials
- Hypertrophic cardiomyopathy 20 0 trials
- Hypertrophic cardiomyopathy 21 0 trials
- Hypertrophic cardiomyopathy 25 0 trials
- Hypertrophic cardiomyopathy 26 0 trials
- Hypertrophic cardiomyopathy 3 0 trials
- Hypertrophic cardiomyopathy 4 0 trials
- Hypertrophic cardiomyopathy 6 0 trials
- Hypertrophic cardiomyopathy 7 0 trials
- Hypertrophic cardiomyopathy 8 0 trials
- Hypertrophic cardiomyopathy 9 0 trials
- Long chain acyl-CoA dehydrogenase deficiency 0 trials
Most studied deeper sub-types
-
Heart drug trial halted early: MYK-224 studied for thick heart muscle
Disease control Stopped earlyThis study tested an experimental drug called MYK-224 in 18 adults with a type of heart disease that makes the heart muscle too thick and blocks blood flow. The goal was to see if the drug is safe and helps reduce symptoms. The trial was stopped early, so results are limited.
Phase 2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Experimental heart slicing procedure tested on one patient
Disease control Stopped earlyThis early study tested a new procedure called SESAME that uses a wire threaded through blood vessels to slice away excess heart muscle in people with hypertrophic cardiomyopathy. Only one adult participated before the study was terminated. The goal was to see if the technique co…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Heart drug mavacamten tested in Non-Obstructive HCM trial
Symptom relief Stopped earlyThis Phase 3 study tested the drug mavacamten in 580 adults with symptomatic non-obstructive hypertrophic cardiomyopathy, a heart muscle condition that makes it harder for the heart to pump blood. Participants received either mavacamten or a placebo. The study measured changes in…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Heart pacemaker tweak aimed at easing chest pain and fatigue – but study stopped early
Symptom relief Stopped earlyThis study tested whether a personalized pacing algorithm (myPACE+) could improve quality of life and exercise capacity in people with non-obstructive hypertrophic cardiomyopathy who already have an implantable defibrillator. Only one person was enrolled before the trial was term…
Sponsor: Montefiore Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:04 UTC
-
Heart Disease's hidden toll: study tracks quality of life across mind, body, and spirit
Knowledge-focused Stopped earlyResearchers at the Cleveland Clinic are following 380 adults with hypertrophic cardiomyopathy, thoracic aortic dilatation, or radiation-induced heart disease. Participants complete a detailed survey at the start and again nine months later. The survey measures global, physical, e…
Sponsor: The Cleveland Clinic • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
AI helps Non-Experts perform heart scans in rare heart condition
Knowledge-focused Stopped earlyThis study looked at whether healthcare workers without ultrasound training could use AI software to perform heart scans on people with hypertrophic obstructive cardiomyopathy (HOCM) who are eligible for the drug mavacamten. Participants had two scans on the same day: one by a no…
Sponsor: UltraSight • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC